Implementing Intravenous Eptinezumab in Routine Migraine Care: A Mixed-Methods Study of Patient and Healthcare Professional Perspectives

INTRODUCTION: Eptinezumab is a calcitonin gene-related peptide monoclonal antibody (CGRP mAb) for migraine prevention, offering rapid onset and quarterly intravenous administration. However, evidence regarding patient and healthcare professional (HCP) experiences and its implementation in routine practice remains limited. This study has explored the opportunities and challenges of eptinezumab treatment. METHODS: This convergent mixed-methods study was conducted at King Chulalongkorn Memorial Hospital, Bangkok, Thailand. A total of 20 patients with migraine who received eptinezumab and 10 HCPs participated. Monthly headache days (MHDs) and Migraine Disability Assessment (MIDAS) scores were evaluated over 6 months for patients. Semi-structured in-depth interviews explored experiences with eptinezumab treatment for both participant groups, with transcripts analyzed using thematic analysis. RESULTS: Median MHDs decreased from 18.5 (IQR 8.5-28.0) at baseline to 5.0 (2.0-8.0) at Month 3 and 2.5 (1.0-5.0) at Month 6. Median MIDAS scores decreased from 63.5 (30.0-77.5) to 15.0 (1.0-33.0) and 5.0 (0.5-19.5), respectively. Qualitative findings identified three opportunities: improved migraine symptoms and quality of life, favorable treatment experience and acceptability, and addressing unmet needs in patients with migraine who had experienced multiple preventive treatment failures. Patients and HCPs described improved migraine control, restored daily functioning, and favorable tolerability. Three major challenges emerged: financial and access barriers, health-system and service delivery challenges, and treatment-related concerns. High costs and limited reimbursement were the predominant barriers identified by both participant groups. CONCLUSIONS: Patients and HCPs perceived eptinezumab as an effective and well-accepted preventive treatment. Although quarterly intravenous administration was viewed favorably, financial barriers and healthcare system constraints remain major obstacles to broader implementation. These findings offer practical insights into integrating CGRP-targeting therapies into routine care. TRIAL REGISTRATION NUMBER: NCT07035197 (ClinicalTrials.gov).

Authors

Institutions

Publication Details

Journal
Neurology and Therapy
Published
2026-11-18
DOI
https://doi.org/10.1007/s40120-026-01089-6
Primary Topic
Migraine and Headache Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Implementing Intravenous Eptinezumab in Routine Migraine Care: A Mixed-Methods Study of Patient and Healthcare Professional Perspectives

Akarin Hiransuthikul, Thanakit Pongpitakmetha, Tanabodee Payuha, Wanakorn Rattanawong et al.
4 links
Neurology and Therapy
Migraine and Headache Studies
article

Implementing Intravenous Eptinezumab in Routine Migraine Care: A Mixed-Methods Study of Patient and Healthcare Professional Perspectives

Akarin Hiransuthikul, Thanakit Pongpitakmetha, Tanabodee Payuha, Wanakorn Rattanawong, Prakit Anukoolwittaya, Sekh Thanprasertsuk, Kanokwan Sinchai
article en

Abstract

INTRODUCTION: Eptinezumab is a calcitonin gene-related peptide monoclonal antibody (CGRP mAb) for migraine prevention, offering rapid onset and quarterly intravenous administration. However, evidence regarding patient and healthcare professional (HCP) experiences and its implementation in routine practice remains limited. This study has explored the opportunities and challenges of eptinezumab treatment. METHODS: This convergent mixed-methods study was conducted at King Chulalongkorn Memorial Hospital, Bangkok, Thailand. A total of 20 patients with migraine who received eptinezumab and 10 HCPs participated. Monthly headache days (MHDs) and Migraine Disability Assessment (MIDAS) scores were evaluated over 6 months for patients. Semi-structured in-depth interviews explored experiences with eptinezumab treatment for both participant groups, with transcripts analyzed using thematic analysis. RESULTS: Median MHDs decreased from 18.5 (IQR 8.5-28.0) at baseline to 5.0 (2.0-8.0) at Month 3 and 2.5 (1.0-5.0) at Month 6. Median MIDAS scores decreased from 63.5 (30.0-77.5) to 15.0 (1.0-33.0) and 5.0 (0.5-19.5), respectively. Qualitative findings identified three opportunities: improved migraine symptoms and quality of life, favorable treatment experience and acceptability, and addressing unmet needs in patients with migraine who had experienced multiple preventive treatment failures. Patients and HCPs described improved migraine control, restored daily functioning, and favorable tolerability. Three major challenges emerged: financial and access barriers, health-system and service delivery challenges, and treatment-related concerns. High costs and limited reimbursement were the predominant barriers identified by both participant groups. CONCLUSIONS: Patients and HCPs perceived eptinezumab as an effective and well-accepted preventive treatment. Although quarterly intravenous administration was viewed favorably, financial barriers and healthcare system constraints remain major obstacles to broader implementation. These findings offer practical insights into integrating CGRP-targeting therapies into routine care. TRIAL REGISTRATION NUMBER: NCT07035197 (ClinicalTrials.gov).

Neurology and Therapy
Chulalongkorn University (TH), King Chulalongkorn Memorial Hospital (TH), King Mongkut's Institute of Technology Ladkrabang (TH)
H. Lundbeck A/S
Good health and well-being
Migraine and Headache Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon